C
Claire Germain
Researcher at French Institute of Health and Medical Research
Publications - 15
Citations - 1446
Claire Germain is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 9, co-authored 12 publications receiving 985 citations. Previous affiliations of Claire Germain include Paris Descartes University & University of Nice Sophia Antipolis.
Papers
More filters
Journal ArticleDOI
Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer
Claire Germain,Sacha Gnjatic,Fella Tamzalit,Samantha Knockaert,Romain Remark,Jeremy Goc,Alice Lepelley,Etienne Becht,Sandrine Katsahian,Geoffray Bizouard,Pierre Validire,Diane Damotte,Marco Alifano,Pierre Magdeleinat,Isabelle Cremer,Jean-Luc Teillaud,Wolf H. Fridman,Catherine Sautès-Fridman,Marie-Caroline Dieu-Nosjean +18 more
TL;DR: B-cell density represents a new prognostic biomarker for NSCLC patient survival, and makes the link between TLS and a protective B cell-mediated immunity.
Journal ArticleDOI
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Jeremy Goc,Claire Germain,Thi Kim Duy Vo-Bourgais,Audrey Lupo,Christophe Klein,Samantha Knockaert,Luc de Chaisemartin,Hanane Ouakrim,Etienne Becht,Marco Alifano,Pierre Validire,Romain Remark,Scott A. Hammond,Isabelle Cremer,Diane Damotte,Wolf H. Fridman,Catherine Sautès-Fridman,Marie-Caroline Dieu-Nosjean +17 more
TL;DR: These results show how tumors infiltrated by TLS-associated mature DC generate a specific immune contexture characterized by a strong Th1 and cytotoxic orientation that confers the lowest risk of death.
Journal ArticleDOI
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
Jérôme Biton,Jérôme Biton,Audrey Mansuet-Lupo,Nicolas Pécuchet,Marco Alifano,Hanane Ouakrim,Hanane Ouakrim,Jennifer Arrondeau,Pascaline Boudou-Rouquette,François Goldwasser,Karen Leroy,Jeremy Goc,Jeremy Goc,Marie Wislez,Claire Germain,Claire Germain,Pierre Laurent-Puig,Pierre Laurent-Puig,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Isabelle Cremer,Isabelle Cremer,Ronald Herbst,Hélène Blons,Hélène Blons,Diane Damotte +25 more
TL;DR: This study reveals that different combinations of TP53, EGFR, and STK11 mutations, together with PD-L1 expression by tumor cells, represent robust parameters to identify best responders to PD-1 blockade.
Journal ArticleDOI
Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Jérôme Biton,Hanane Ouakrim,Agnès Dechartres,Marco Alifano,Audrey Mansuet-Lupo,Han Si,Rebecca Halpin,Todd Creasy,Claudie Bantsimba-Malanda,Jennifer Arrondeau,François Goldwasser,Pascaline Boudou-Rouquette,Ludovic Fournel,Nicolas Roche,Pierre-Régis Burgel,Jeremy Goc,Jeremy Goc,Priyanka Devi-Marulkar,Priyanka Devi-Marulkar,Claire Germain,Claire Germain,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Isabelle Cremer,Isabelle Cremer,Ronald Herbst,Diane Damotte +26 more
TL;DR: COPD is associated with an increased sensitivity of CD8 tumor‐infiltrating T lymphocytes to immune escape mechanisms developed by tumors, thus suggesting a higher sensitivity to PD‐1 blockade in patients with COPD.
Journal ArticleDOI
MHC Class I–Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells
Claire Germain,Christel Larbouret,Valérie Cesson,Alena Donda,Werner Held,Jean-Pierre Mach,André Pèlegrin,Bruno Robert +7 more
TL;DR: Results open the way to the development of immunotherapy strategies based on antibody-mediated targeting of MICA, and preincubation of the tumor cells with the appropriate Fab-rMICA conjugate resulted in NK cell–mediated tumor cell lysis.